Vol 5, No 4 (2009)
Case report
Published online: 2009-07-30
Metastatic breast cancer in young woman: capecitabine monotherapy after failure of the targeted therapy - a case report
Onkol. Prak. Klin 2009;5(4):158-162.
Abstract
Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women with
metastatic HER2-positve breast cancer progressing during trastuzumab and lapatinib treatment. This is
a case report concerning anthracycline- and taxane-resistant advanced breast cancer in a young woman
and the treatment after failure of the targeted therapy.
Keywords: metastatic breast cancerHER2-targeted therapycapecitabine
References
- Sidoni A, Cavaliere A, Bellezza G, et al. Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003; 12(4): 247–250.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783–792.
- Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23(19): 4265–4274.
- Bell R, Verma S, Untch M, et al. Maximizing clinical benefit with trastuzumab. Semin Oncol. 2004; 31(5 Suppl 10): 35–44.
- Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol. 2006; 17(4): 630–636.
- von Minckwitz G, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). Journal of Clinical Oncology. 2008; 26(15_suppl): 1025–1025.
- Yamamoto D, Iwase S, Kitamura K, et al. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol. 2008; 61(3): 509–514.
- Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007; 25(25): 3853–3858.
- Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005; 6(5): 425–432.
- O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004; 5(2): 142–147.
- Gelman KA, Fumleau P, Verma S, et al. Result of a phase II trial of trastuzumab and partuzumab in patients with HER2-positive metastatic breast cancer who had progressed during trastuzumab therapy. . Proc. Am. Soc. Clin. Oncol. 2008; 26: 47s. abstract 1026.
- Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23(23): 5305–5313.
- O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Journal of Clinical Oncology. 2008; 26(15_suppl): 1015–1015.
- Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112(3): 533–543.
- Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26): 2733–2743.
- Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in HER2-positive breast cancer. Curr Oncol Rep. 2008; 10(1): 10–17.
- Venturini M, Paridaens R, Rossner D, et al. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology. 2007; 72(1-2): 51–57.
- Osako T, Ito Y, Takahashi S, et al. Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer. Tumori. 2007; 93(2): 129–132.
- Siva M, Correa P, Skaria S, et al. Capecitabine in advanced breast cancer: Predictive factors for response. Journal of Clinical Oncology. 2008; 26(15_suppl): 1126–1126.
- Di Costanzo F, Gasperoni S, Papaldo P, et al. Gruppo Oncologico Italiano di Ricerca clinica, Gruppo Oncologico del Lazio. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. Ann Oncol. 2006; 17(1): 79–84.
- O'Shaughnessy JA, Blum JL. Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer. Clin Breast Cancer. 2006; 7(1): 42–50.
- Benekli M, Yildiz R, Uner A, et al. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology. 2007; 72(5-6): 308–313.
- Estévez LG, Batista N, Sánchez-Rovira P, et al. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2008; 8(2): 149–154.
- Massacesi C, La Cesa A, Marcucci F, et al. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology. 2006; 70(4): 294–300.